Transcode Therapeutics, Inc.(RNAZ)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
RNAZ Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Transcode Therapeutics, Inc. (RNAZ), a Healthcare sector company. RNAZ is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of RNAZ by reported 13-F value include Yorkville Advisors Global, VANGUARD CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. RNAZ trades on the Nasdaq exchange and files with the SEC under CIK 1829635. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNAZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Transcode Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-6.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-106.9% YoYOperating Income
-78.7% YoYEPS (Diluted)
+96.1% YoYTotal Assets
+2126.3% YoYOp. Cash Flow
-46.3% YoYFree Cash Flow
-46.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-34.7M -106.9% | $-16.8M +9.7% | $-18.5M -5.6% | $-17.6M -156.7% | $-6.8M -192.0% | $-2.3M |
| Operating Income | $-28.0M -78.7% | $-15.7M +19.4% | $-19.4M -4.2% | $-18.6M -202.9% | $-6.2M -746.6% | $-726.6K |
| EPS (Diluted) | $-52.59 +96.1% | $-1336.63 +60.9% | $-3419.01 -215.8% | $-1082.79 -133577.8% | $-0.81 -58.8% | $-0.51 |
| Total Assets | $162.4M +2126.3% | $7.3M +41.1% | $5.2M -31.9% | $7.6M -66.9% | $22.9M +2073.5% | $1.1M |
| Operating Cash Flow | $-19.5M -46.3% | $-13.3M +26.2% | $-18.1M -14.7% | $-15.8M -199.3% | $-5.3M -968.4% | $-493.0K |
| Free Cash Flow | $-19.5M -46.2% | $-13.4M +26.2% | $-18.1M -14.2% | $-15.9M -187.3% | $-5.5M | — |
Get alerted when RNAZ's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Transcode Therapeutics, Inc. including:
Top Institutional Holders of RNAZ
Yorkville Advisors Global, LP
$122.0K19,639 shVANGUARD CAPITAL MANAGEMENT LLC
$40.6K6,545 shVANGUARD FIDUCIARY TRUST CO
$18.5K2,982 shUBS Group AG
$17.9K2,888 shFMR LLC
$4.4K706 shTower Research Capital LLC (TRC)
$4.2K677 shWELLS FARGO & COMPANY/MN
$342.0055 shSBI Securities Co., Ltd.
$75.0012 sh
| Fund | Value | Shares |
|---|---|---|
| Yorkville Advisors Global, LP | $122.0K | 19,639 |
| VANGUARD CAPITAL MANAGEMENT LLC | $40.6K | 6,545 |
| VANGUARD FIDUCIARY TRUST CO | $18.5K | 2,982 |
| UBS Group AG | $17.9K | 2,888 |
| FMR LLC | $4.4K | 706 |
| Tower Research Capital LLC (TRC) | $4.2K | 677 |
| WELLS FARGO & COMPANY/MN | $342.00 | 55 |
| SBI Securities Co., Ltd. | $75.00 | 12 |
More Healthcare Companies
View all Healthcare →Put RNAZ on your watchlist
Track score changes the day Transcode Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RNAZ a good stock to buy?
13F Pro's AI-powered analysis of Transcode Therapeutics, Inc. (RNAZ) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RNAZ are available on the RNAZ stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RNAZ is classified as a small company.
Which hedge funds own RNAZ?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RNAZ. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Transcode Therapeutics, Inc.'s investment landscape.